Objective: To observe the clinical effect of Jinlida granules combined with alpha-lipoic acid on type 2 diabetic peripheral neuropathy (DPN). Methods: A total of 62 type 2 diabetic patients with DPN from August 2016 to October 2017 in Second Hospital of Jilin University were randomly divided into a treatment group and a control group, with 31 in each group. The control group received alpha-lipoic acid 0.6 g/d in normal saline 250 mL given by intravenous once a day during the hospital, and then changed to alpha-lipoic acid capsule (0.2 g/time, 3 times/d) after discharge. The treatment group was added Jinlida granules (9 g/time, 3 times/d) on the basis of the control group. The treatment lasted for 12 weeks. The changes of symptoms and signs, Toronto clinical scoring system (TCSS) score, nerve conduction velocity, fasting blood glucose (FPG), 2 h PG and HbA1c were measured and compared. Results: After 12 weeks of treatment, the effective rate in the treatment group was significantly higher than that in the control group (P<0.05). Compared with before treatment, the TCSS score was decreased and the nerve conduction velocity was accelerated significantly after 12 weeks of treatment in both groups (all P<0.05), and the difference of the treatment group was more obvious, with statistical significance (P<0.05). After treatment, FPG, 2 h PG and HbA1c in the treatment group tended to decrease compared with the control group, but the difference was not statistically significant (P>0.05). Conclusion: Jinlida granules combined with alpha-lipoic acid in the treatment of type 2 DPN not only can improve the clinical symptoms but also accelerate the nerve conduction velocity, and the curative effect is definite.